Serotonin Control of Impulsivity in Tourette Disorder

Tourette Disorder Clinical Trial

— ARITEP  

Official title:

Involvement of the Serotonergic System in the Control of Impulsivity in Tourette Disorder.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05942716
• Other study ID #: 69HCL22_0683
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: December 1, 2023
• Est. completion date: December 1, 2027

Study information

• Verified date: June 2023
• Source: Hospices Civils de Lyon
• Contact: Benjamin PASQUEREAU
• Phone: +33 437 911 241
• Email: benjamin.pasquereau[@]isc.cnrs.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Tourette disorder (TD) is a neurodevelopmental disorder characterized by motor and vocal tics. It is often associated with multiple psychiatric comorbidities involving a high degree of impulsivity such as obsessive-compulsive disorders (OCD), attention-deficit hyperactivity disorders (ADHD), and intermittent explosive disorders (IED). Although a substantial body of clinical studies have emphasized the role of the dopamine system in motor symptoms, little is known about how the serotonergic (5-HT) system modulate both cognitive and affective abilities in TD. Several lines of evidence suggest that different 5-HT receptor subtypes may constitute a crucial factor in the development and maintenance of different symptoms. Because abnormal 5-HT2A receptor bindings have been reported in patients with TD and aripiprazole (drug of first choice) is a 5-HT2A antagonist, we hypothesize that 5-HT2A receptors may play an important role in regulating psychiatric symptoms in TD such as those characterized by impulsive behaviors. To investigate the involvement of 5-HT2A receptors in TD, we propose to perform a multimodal imaging study with 20 adult patients (ON and OFF treatment). Neuroimaging data will be collected with a hybrid system that simultaneously combines the positron emission tomography (PET) and the functional magnetic resonance imaging (fMRI). A highly selective PET radiotracer ([18F]-altanserin) will map 5-HT2A receptor bindings in the whole brain, while fMRI will provide detail information regarding the altered brain activities.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: December 1, 2027
• Est. primary completion date: December 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

• Inclusion Criteria * :
• Male or Female
• Diagnosed with a Tourette Disorder following the DSM-5
• Age between 18-65 years
• Member of a social security scheme in France
• Freely-given informed consent to participate to this study (written form)
• With a current treatment by aripiprazole already scheduled
• With Tics compatible with TEP/fMRI exams
• Having (for women only) effective contraception throughout participation in the study.

Exclusion Criteria * :

• Male or Female
• A serious not controlled psychiatric comorbidity
• A serious, evolving or debilitating pathology with a potential influence on the study
• Drug-taking with serotonergic effects (e.g., amphetamine, cocaine, MDMA, SSRIs, mianserin)
• Contraindication for fMRI and PET (e.g., pacemaker, ferromagnetic implant, claustrophobia)
• Women breastfeeding
• Protected or restricted person (administratively or in judicial terms)
• Participants to another study with radiations or radiotracers since less of one year, participants to a concomitant study
• Do not speak french

Related Conditions & MeSH terms

• Impulsive Behavior
• Tourette Disorder
• Tourette Syndrome

Intervention

Drug:
• Administration of a PET radiotracer
A highly selective 5-HT2A receptor ligand ([18F]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine. Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic.

Locations

Country	Name	City	State
France	Service de neurologie C Hôpital neurologique Pierre Wertheimer/GHE Hospices Civils de Lyon	Bron
France	Centre de Référence Syndrome Gilles de la Tourette Département de Neurologie Pôle des Maladies du Système Nerveux Hôpital de la Pitié-Salpêtrière	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation coefficients between receptor-specific imaging data (PET) and scores of impulsivity measured by the Barratt scale (BIS11).	Correlation coefficients between changes in the binding potential (BPND) of [18F]-altanserin measured voxel-by-voxel in the whole brain and the evolution of scores BIS11 in TD patients.	As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.
Secondary	Correlation coefficients between receptor-specific imaging data (PET) and other clinical/behavioral scores.	Correlation coefficients between changes in the binding potential (BPND) of [18F]-altanserin measured voxel-by-voxel in the whole brain and the evolution of other clinical scores and task performance of TD patients.	As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.
Secondary	Correlation coefficients between functional imaging data (fMRI) and scores of impulsivity measured by the Barratt scale (BIS11).	Correlation coefficients between changes in the BOLD signal measured voxel-by-voxel in the whole brain and the evolution of scores BIS11 in TD patients.	As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.
Secondary	Correlation coefficients between functional imaging data (fMRI) and other clinical/behavioral scores.	Correlation coefficients between changes in the BOLD signal measured voxel-by-voxel in the whole brain and the evolution of other clinical scores and task performance of TD patients.	As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.